TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI
Neuraxpharm’s dedicated neurology focus and established European presence makes them an attractive partner for BRIUMVI’s European launch, targeted…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
02 Aug 23
Neuraxpharm’s dedicated neurology focus and established European presence makes them an attractive partner for BRIUMVI’s European launch, targeted…
28 Jul 23
Under the agreement, AstraZeneca will acquire and license the assets of Pfizer's early-stage rare disease gene therapy portfolio,…
26 Jul 23
PeptiDream will receive an upfront payment of JPY3bn ($21m) and is eligible to receive discovery, development and commercial…
26 Jul 23
The primary objective of the collaboration is to make Pillar's suite of oncology assays available worldwide, adding a…
25 Jul 23
Zilebesiran is an investigational, subcutaneously administered RNAi therapeutic that targets angiotensinogen (AGT), which regulates blood pressure and fluid…
25 Jul 23
The centrepiece of the agreement entails SpectronRx taking on the responsibility of manufacturing a vital component of ARTBIO's…
24 Jul 23
The collaboration will now include the exclusive commercialisation in the US by Teva of two new biosimilar candidates…
21 Jul 23
With the help of the Wellcome Trust, LimmaTech Bio and GSK have formed a research partnership to create…
21 Jul 23
By combining the strengths of both companies, the strategic research collaboration aims to develop more effective and precise…
20 Jul 23
As part of the collaboration, life science companies will have access to a comprehensive de-identified dataset that specifically…